Compare PRLB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | TSHA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2011 | 2020 |
| Metric | PRLB | TSHA |
|---|---|---|
| Price | $79.64 | $6.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $53.00 | $11.63 |
| AVG Volume (30 Days) | 205.6K | ★ 2.8M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 5.56 |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $6.89 | $1,152.42 |
| P/E Ratio | $246.12 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $38.48 | $2.25 |
| 52 Week High | $83.15 | $7.30 |
| Indicator | PRLB | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 52.09 |
| Support Level | $52.62 | $6.11 |
| Resistance Level | $83.15 | $6.76 |
| Average True Range (ATR) | 2.98 | 0.42 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 65.02 | 49.86 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.